Abstract

Fibroblast growth factor receptor 4 (FGFR4) is involved in multiple physiological and pathological processes. Several genetic variants of FGFR4 have been shown to be associated with tumor progression in many cancers. However, its association, such as genetic variants and expression levels, with lung cancer is controversial. The present study examined the relationship between four single-nucleotide polymorphisms (SNPs; rs2011077 T/C, rs351855 G/A, rs7708357 G/A, and rs1966265 A/G) of FGFR4 and the risk of lung adenocarcinoma with the epidermal growth factor receptor (EGFR) mutation status in a Taiwanese cohort. The results demonstrated that FGFR4 rs2011077 (odds ratio (OR) = 0.348, 95% confidence interval (CI) = 0.136–0.891, p = 0.024), and rs351855 (OR = 0.296, 95% CI = 0.116–0.751, p = 0.008) showed an inverse association with distant metastasis in wild-type EGFR lung adenocarcinoma. Furthermore, a database analysis using The Cancer Genome Atlas revealed that the higher FGFR4 expression level was correlated with poor survival rates in wild-type EGFR lung adenocarcinoma. In conclusion, the data suggest that FGFR4 SNPs may help in identifying patient subgroups at low-risk for tumor metastasis, among carriers of lung adenocarcinoma bearing wild-type EGFR.

Highlights

  • Lung cancer has the highest global incidence and mortality rate of all cancers [1]

  • We studied the effect of Fibroblast growth factor receptor 4 (FGFR4) Single nucleotide polymorphism (SNP) on the clinicopathological characteristics of lung adenocarcinoma with and without epidermal growth factor receptor (EGFR) mutation

  • The data indicate that both FGFR4 SNPs rs2011077 and rs351855 may be associated with reduced presence of distant metastasis in Taiwanese patients with lung adenocarcinoma, especially those with the wild-type EGFR gene

Read more

Summary

Introduction

Lung cancer has the highest global incidence and mortality rate of all cancers [1]. According to statistical data from Taiwan’s Ministry of Health and Welfare, the leading causes of cancer-related death in 2018 were tracheal, bronchial, and lung cancer. 50% of lung cancer cases, occurs frequently in the female and nonsmoking populations [2,3]. In addition to environmental risk factors such as smoking and exposure to certain chemicals, genetic variation increases the risk of lung cancer. Up to 30% of patients with lung adenocarcinoma in the Asian population have been shown to harbor epidermal growth factor receptor (EGFR) mutations [4,5]. The identification of other biomarkers and novel treatment strategies for lung adenocarcinoma is an unmet need

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.